Disease · MONDO_0004643
Targets114
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 114
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 6 | Tyrosine-protein kinase receptor FLT3 inhibitor | Approval | https://conductscience.org/library/genes/2322 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 6 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Approval | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 3 | Bcr/Abl fusion protein inhibitor | Approval | https://conductscience.org/library/genes/613 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 3 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 3 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | 3 | Tyrosine-protein kinase receptor RET inhibitor | Approval | https://conductscience.org/library/genes/5979 | Drugs and targets |
| TOP2B | DNA topoisomerase II | 3 | DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7155 | Drugs and targets |
| AXL | Tyrosine-protein kinase receptor UFO | 2 | Tyrosine-protein kinase receptor UFO inhibitor | Approval | https://conductscience.org/library/genes/558 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 2 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Approval | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 2 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Approval | https://conductscience.org/library/genes/1788 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 2 | Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5156 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5425 | Drugs and targets |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/10714 | Drugs and targets |
| POLD4 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/57804 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004643/targets